Navigation Links
Nano Mask Names Dr. Hassan Bennani to Board of Directors
Date:1/24/2013

FISHKILL, N.Y., Jan. 24, 2013 /PRNewswire/ -- Nano Mask, Inc., (PINKSHEETS: NANM), a materials technology development company focused on health and wellness related markets, today announced that it has appointed Hassan Bennani , MD, to its Board of Directors.

Dr. Bennani is the co-founder and CEO of KellBenx, Incorporated, a closely held Long Island, NY based biotechnology company focused on women's healthcare, concentrating on the development of a patented breakthrough non-invasive prenatal diagnostic (NIPD) for analyzing genetic disorders and a patent pending breakthrough test to determine a woman's risk of preterm delivery.

Dr. Bennani was previously the head of business development at Lenetix, a women's health focused lab acquired by Bio-Reference Laboratories.  Prior to that, Dr. Bennani was a Vice President of Sales and Marketing for Adeza Biomedical Corporation, which was acquired by Hologic.  

"I am excited about joining forces with Nano Mask , which has assembled an impressive hospital textile product portfolio that can grow its sales significantly over the next few years," said Dr. Bennani, who went on to add, "I am confident that the industry contacts that I have made over the course of my career, especially in international markets, will be very receptive to Nano Mask 's products."

"Dr. Bennani's extensive experience and network make him ideally suited to help promote our products both in the United States and internationally," said Edward Suydam , President and CEO, Nano Mask Inc.

About Nano Mask , Inc.

We are a healthcare product development and distribution company providing innovative and cost effective emergency and critical care and infection control products to a variety of market segments within the healthcare industry. Our customers range from hospitals, emergency services, surgery centers, long-term care facilities, nursing homes and other clinical settings throughout the healthcare continuum.

Forward-looking Statement

This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. Specifically, any unforeseen delays in manufacturing and distribution may affect sales of NMI products. NMI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.

Contact:

For further information:
Ed Suydam (914) 760-7857 eds@nmihealth.com

 

 

 

 


'/>"/>
SOURCE Nano Mask , Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SPIE Names 69 New Fellows of the Society in 2013
2. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
3. AtheroNova Names New Director
4. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
5. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
6. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
7. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
8. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
9. Lloyd Library and Museum Names ABCs Blumenthal to New Honorary Advisory Board
10. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
11. Triple-S Management Corporation Announces the Retirement of Socorro Rivas-Rodriguez; Names Pablo Almodovar Scalley as Successor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... FRANKLIN LAKES, N.J. , Jan. 18, 2017 BD ... medical technology company, announced today that it will host a live ... 2017, at 1 p.m. (ET). The webcast can ... will be available for replay through Tuesday, January 31, 2017. ... About BD ...
(Date:1/18/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, will feature data from two clinical ... 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, ... Napabucasin is an orally-administered investigational agent designed to ... Cancer stem cells (CSCs) possess the property of stemness ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone Partners ... commitment to the advancement of the clinical trials segment. Hosted in Miami, this ... trial planning and management. , As executive talent specialists in the industries ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in December 2016, RoosterBio ... U.S. Secretary of Commerce Penny Pritzker has announced the award of a new ... has announced the award of a new Advanced Regenerative Manufacturing Institute (ARMI). These ...
Breaking Biology Technology:
(Date:12/7/2016)... December 7, 2016 According to a new market research ... Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region - ... grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, ... Continue Reading ... MarketsandMarkets Logo ...
(Date:12/7/2016)... Dec. 7, 2016   Avanade is helping ... One teams in history, exploit biometric data in order ... and maintain the competitive edge against their rivals after ... Avanade has worked with Williams during the ... biometric data (heart rate, breathing rate, temperature and peak ...
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
Breaking Biology News(10 mins):